SLC22A5 antibody

Product Graph
Contáctenos para saber el precio

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
SLC22A5 antibody
category
Primary Antibodies
provider
FineTest
reference
FNab05966
tested applications
ELISA, WB, IHC

Documents del producto

Instrucciones
Descargar
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
solute carrier family 22(organic cation/carnitine transporter), member 5 (SLC22A5)
Host
Rabbit
Reactivity
Human, Mouse, Rat
Recommended Dilution
WB: 1:500-1:1000; IHC: 1:20-1:200
Clonality
polyclonal
Conjugation
Unconjugated
Isotype
IgG
Observed MW
75 kDa
Purity
≥95% as determined by SDS-PAGE
Purification
Immunogen affinity purified
Size 1
100µg
Form
liquid
Tested Applications
ELISA, WB, IHC
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
UniProt ID
O76082
Alias
Organic cation/carnitine transporter 2,High-affinity sodium-dependent carnitine cotransporter,Solute carrier family 22 member 5,SLC22A5,OCTN2
Background
Antibody anti-SLC22A5
Status
RUO
Note
Mol. Weight 75 kDa

Related Products

FNab05966

SLC22A5 antibody

Ver Producto
P9026

Recombinant Human SLC22A5

Ver Producto
abx001408

Solute Carrier Family 22 Member 5 (SLC22A5) Antibody

SLC22A5 Antibody is a Rabbit Polyclonal antibody against SLC22A5. Polyspecific organic cation transporters in the liver, kidney, intestine, and other organs are critical for elimination of many endogenous small organic cations as well as a wide array of drugs and environmental toxins. The encoded protein is a plasma integral membrane protein which functions both as an organic cation transporter and as a sodium-dependent high affinity carnitine transporter. The encoded protein is involved in the active cellular uptake of carnitine. Mutations in this gene are the cause of systemic primary carnitine deficiency (CDSP), an autosomal recessive disorder manifested early in life by hypoketotic hypoglycemia and acute metabolic decompensation, and later in life by skeletal myopathy or cardiomyopathy. [provided by RefSeq, Jul 2008].

Ver Producto